Cognition Therapeutics annual operating income
2020
2021
2022
2023
2024
2025
Cognition Therapeutics Operating Income Growth & History (CGTX)
Cognition Therapeutics's operating income was −$47.8M for fiscal 2025.
View full Cognition Therapeutics company overviewCognition Therapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$47.8M | $6.2M | — |
| 2024 | 2024-12-31 | −$54.0M | −$3.2M | — |
| 2023 | 2023-12-31 | −$50.7M | −$7.2M | — |
| 2022 | 2022-12-31 | −$43.6M | −$15.0M | — |
| 2021 | 2021-12-31 | −$28.6M | −$11.2M | — |
| 2020 | 2020-12-31 | −$17.4M | — | — |
Cognition Therapeutics quarterly operating income
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.7M | $6.2M | — |
| Q1 2026 | 2026-03-31 | −$8.8M | $5.0M | — |
| Q4 2025 | 2025-12-31 | −$13.7M | −$2.9M | — |
| Q3 2025 | 2025-09-30 | −$6.4M | $8.1M | — |
| Q2 2025 | 2025-06-30 | −$14.0M | $700,000 | — |
| Q1 2025 | 2025-03-31 | −$13.8M | $327,000 | — |
| Q4 2024 | 2024-12-31 | −$10.7M | $4.5M | — |
| Q3 2024 | 2024-09-30 | −$14.5M | $282,000 | — |
| Q2 2024 | 2024-06-30 | −$14.7M | −$2.9M | — |
| Q1 2024 | 2024-03-31 | −$14.1M | −$5.1M | — |
| Q4 2023 | 2023-12-31 | −$15.2M | −$5.9M | — |
| Q3 2023 | 2023-09-30 | −$14.7M | −$2.1M | — |
| Q2 2023 | 2023-06-30 | −$11.8M | $396,000 | — |
| Q1 2023 | 2023-03-31 | −$9.0M | $440,000 | — |
| Q4 2022 | 2022-12-31 | −$9.3M | $2.5M | — |
| Q3 2022 | 2022-09-30 | −$12.6M | −$7.4M | — |
| Q2 2022 | 2022-06-30 | −$12.2M | −$6.2M | — |
| Q1 2022 | 2022-03-31 | −$9.4M | −$3.8M | — |
| Q4 2021 | 2021-12-31 | −$11.8M | — | — |
| Q3 2021 | 2021-09-30 | −$5.2M | −$762,000 | — |
| Q2 2021 | 2021-06-30 | −$6.0M | — | — |
| Q1 2021 | 2021-03-31 | −$5.6M | — | — |
| Q3 2020 | 2020-09-30 | −$4.5M | — | — |
Cognition Therapeutics operating income trends
Over the last five fiscal years, Cognition Therapeutics's operating income decreased from −$17.4M to −$47.8M, a change of −$30.4M. The latest reported quarter, Q2 2026, shows −$7.7M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cognition Therapeutics source filings ↗Community posts
Cognition aligns with FDA on pivotal Lewy body dementia trial
Cognition Therapeutics ($CGTX) said it reached agreement with the FDA on key elements of a planned pivotal Phase 3 study of zervimesine, also known as CT1812, in dementia with Lewy bodies. The proposed trial would compare a 100-milligram da ...
